Deramciclane

From Self-sufficiency
Jump to: navigation, search
Deramciclane
220px
Systematic (IUPAC) name
N,N-dimethyl-2-([(1R,4R,6S)-1,7,7-trimethyl-6-phenyl-6-bicyclo[2.2.1]heptanyl]oxy)ethanamine
Identifiers
CAS Number 120444-72-6
ATC code none
PubChem CID 119590
Synonyms Deramciclane
Chemical data
Formula C20H31NO
Molar mass 301.466 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Deramciclane (EGIS-3886) is a drug which acts as an antagonist at the 5-HT2A receptor,[1] as an inverse agonist at the 5-HT2C receptor,[2] and as a GABA reuptake inhibitor.[3] It has anticonvulsant and anxiolytic effects, and has proceeded through to Phase III clinical trials in humans,[4] although development and further trials are still underway and it has not yet been approved for clinical use. Results to date suggest that it is effective and well tolerated for the treatment of anxiety, with the only significant side effect being headaches.[5]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />



  1. Kanerva, H; Vilkman, H; Någren, K; Kilkku, O; Kuoppamäki, M; Syvälahti, E; Hietala, J (1999). "Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study". Psychopharmacology. 145 (1): 76–81. doi:10.1007/s002130051034. PMID 10445375.  edit
  2. Pälvimäki, EP; Majasuo, H; Kuoppamäki, M; Männistö, PT; Syvälahti, E; Hietala, J (1998). "Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation". Psychopharmacology. 136 (2): 99–104. doi:10.1007/s002130050544. PMID 9551765.  edit
  3. Kovács, I; Maksay, G; Simonyi, M (1989). "Inhibition of high-affinity synaptosomal uptake of gamma-aminobutyric acid by a bicyclo-heptane derivative". Arzneimittel-Forschung. 39 (3): 295–7. PMID 2502985.  edit
  4. Kõks, S; Vasar, E (2002). "Deramciclane (Egis)". Current opinion in investigational drugs (London, England : 2000). 3 (2): 289–94. PMID 12020062.  edit
  5. Naukkarinen, H.; Raassina, R.; Penttinen, J.; Ahokas, A.; Jokinen, R.; Koponen, H.; Lepola, U.; Kanerva, H.; Lehtonen, L. (2005). "Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study". European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 15 (6): 617–623. doi:10.1016/j.euroneuro.2005.03.002. PMID 15949921.  edit